|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons
3
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
4
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
5